8-K Announcements
6Material company update
Mar 17, 2026·SEC
Material company update
Dec 12, 2025·SEC
Material company update
Nov 7, 2025·SEC
Longevity Health Holdings Inc.(XAGE)Earnings, Financials & Key Ratios
XAGE•NASDAQ
$0.26
Price updated Jul 7, 2026
AboutLongevity Health Holdings Inc focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.Show more
- Revenue$2M+3701.4%
- EBITDA-$7M-43.6%
- Net Income-$7M+33.4%
- EPS (Diluted)-4.01-702.0%
- Gross Margin57.23%-34.5%
- EBITDA Margin-360.33%+96.2%
- Operating Margin-371.58%+96.3%
- Net Margin-361%+98.2%
XAGE Price & Volume
Longevity Health Holdings Inc. (XAGE) stock price & volume — 10-year historical chart
Loading chart...
Severe Liquidity Erosion Threatens Operational Viability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and insolvency
Key Thesis Takeaways
- Longevity Health Holdings faces a critical existential threat as its asset base has collapsed from $63.9 million in 2023Q4 to a mere $1.6 million by 2026Q1.
- The company's inability to scale commercial operations is evidenced by a 23.2% revenue contraction in the most recent quarter and a persistent failure to achieve positive operating leverage.
- Investors should exercise extreme caution given the negative equity position of $6.9 million and the lack of a clear path to self-sustaining cash flow.
Verdict Logic
the company's precarious liquidity position, highlighted by a cash balance of only $313,400 against significant operational losses, suggests an imminent risk of insolvency or highly dilutive financing.
XAGE Growth Metrics
Longevity Health Holdings Inc. (XAGE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM220.01%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM20.6%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-592.86%
Return on Capital
10 Years-49.97%
5 Years-49.97%
3 Years-49.97%
Last Year-
Peers Comparison
Key metrics vs top competitors for Longevity Health Holdings Inc. (XAGE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.26 | $371.7K | -0.06 | 3701.44% | -361% | — | — | |
| $36.17 | $7.94B | 70.92 | 59% | -0.56% | -2.48% | — | |
| $0.37 | $3.78M | -0.18 | -25.96% | -4632.94% | -120.72% | — | |
| $237.59 | $166.46B | 170.93 | 35.82% | 12.31% | 3.49% | — | |
| $3.03 | $1.05B | 35.52 | 0.57% | 3.74% | 4.75% | — | |
| $5.20 | $871.07M | 130.00 | 22% | 0.49% | 1.03% | — |
Compare XAGE vs Peers
Longevity Health Holdings Inc. (XAGE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
XAGE SEC Filings & Documents
Longevity Health Holdings Inc. (XAGE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when XAGE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
XAGE Frequently Asked Questions
Longevity Health Holdings Inc. (XAGE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Longevity Health Holdings Inc.'s revenue?
Longevity Health Holdings Inc. (XAGE) reported $1.8M in revenue for fiscal year 2025.
How fast is Longevity Health Holdings Inc. growing?
Longevity Health Holdings Inc. (XAGE) grew revenue by 3701.4% over the past year. This is strong growth.
Is XAGE profitable?
Longevity Health Holdings Inc. (XAGE) reported a net loss of $6.8M for fiscal year 2025.
Dividend & Returns
What is Longevity Health Holdings Inc.'s free cash flow?
Longevity Health Holdings Inc. (XAGE) had negative free cash flow of $3.1M in fiscal year 2025, likely due to heavy capital investments.